QTTB · Q32 Bio Inc.

Q32 Bio reported its first quarter 2026 financial results, highlighting a reduced net loss of $7.6 million compared to $11.0 million in the same period last year. The improvement was driven by lower research and development expenses ($3.2 million vs. $7.1 million) due to reduced headcount, lower bempikibart clinical costs, and the sale of the ADX-097 program in November 2025. General and administrative expenses also decreased to $4.5 million from $5.1 million, primarily from lower legal and consulting costs. The company ended the quarter with $50.8 million in cash and cash equivalents, which excludes $14.2 million in gross proceeds from ATM sales received after quarter-end. Combined with guaranteed near-term milestone payments from the ADX-097 asset sale, management expects sufficient runway into the first half of 2028. Operationally, the key catalyst is the expected mid-2026 topline data from Part B of the SIGNAL-AA Phase 2a trial evaluating bempikibart in alopecia areata. The company noted encouraging signs of clinical activity and earlier achievement of steady-state drug concentration due to a loading regimen. The first patient has been dosed in the open-label extension of Part B, and findings from the Part A OLE will be reported alongside Part B results. In February 2026, Q32 Bio completed a $10.5 million registered direct offering, further strengthening its balance sheet. The company remains a clinical-stage biotechnology firm with no approved products, and its near-term value hinges on the bempikibart data readout.